Study finds insufficient physical activity is a global issue, with nearly a third of adults worldwide not getting adequate amounts of exercise in 2022.
New clinical trials presented at the American Diabetes Association's Scientific Sessions show that survodutide has promising results for reducing HbA1c levels and improving insulin sensitivity, with additional favorable changes in glucose-related biomarkers.
New research presented at the American Diabetes Association Scientific Sessions in Orlando, Florida, reveals the significant efficacy of ecnoglutide (XW003), a novel cAMP signaling biased GLP-1 analog, in adults with type 2 diabetes mellitus and obesity in China.